Literature DB >> 33190167

Targeted Proteomics Reveals Inflammatory Pathways that Classify Immune Dysregulation in Common Variable Immunodeficiency.

Roos-Marijn Berbers1, Julia Drylewicz2, Pauline M Ellerbroek3, Joris M van Montfrans4, Virgil A S H Dalm5, P Martin van Hagen5, Baerbel Keller6,7, Klaus Warnatz6,7, Annick van de Ven8, Jaap M van Laar1, Stefan Nierkens2, Helen L Leavis9.   

Abstract

Patients with common variable immunodeficiency (CVID) can develop immune dysregulation complications such as autoimmunity, lymphoproliferation, enteritis, and malignancy, which cause significant morbidity and mortality. We aimed to (i) assess the potential of serum proteomics in stratifying patients with immune dysregulation using two independent cohorts and (ii) identify cytokine and chemokine signaling pathways that underlie immune dysregulation in CVID. A panel of 180 markers was measured in two multicenter CVID cohorts using Olink Protein Extension Assay technology. A classification algorithm was trained to distinguish CVID with immune dysregulation (CVIDid, n = 14) from CVID with infections only (CVIDio, n = 16) in the training cohort, and validated on a second testing cohort (CVIDid n = 23, CVIDio n = 24). Differential expression in both cohorts was used to determine relevant signaling pathways. An elastic net classifier using MILR1, LILRB4, IL10, IL12RB1, and CD83 could discriminate between CVIDid and CVIDio patients with a sensitivity of 0.83, specificity of 0.75, and area under the curve of 0.73 in an independent testing cohort. Activated pathways (fold change > 1.5, FDR-adjusted p < 0.05) in CVIDid included Th1 and Th17-associated signaling, as well as IL10 and other immune regulatory markers (LAG3, TNFRSF9, CD83). Targeted serum proteomics provided an accurate and reproducible tool to discriminate between patients with CVIDid and CVIDio. Cytokine profiles provided insight into activation of Th1 and Th17 pathways and indicate a possible role for chronic inflammation and exhaustion in immune dysregulation. These findings serve as a first step towards the development of biomarkers for immune dysregulation in CVID.

Entities:  

Keywords:  Biomarkers; Common variable immunodeficiency (CVID); Cytokines; Immune dysregulation; Prediction; Primary immunodeficiency

Mesh:

Substances:

Year:  2020        PMID: 33190167      PMCID: PMC7858548          DOI: 10.1007/s10875-020-00908-1

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  43 in total

1.  Unravelling the complexity of T cell abnormalities in common variable immunodeficiency.

Authors:  Antonello Giovannetti; Marina Pierdominici; Francesca Mazzetta; Marco Marziali; Cristina Renzi; Anna Maria Mileo; Marco De Felice; Barbara Mora; Antonella Esposito; Rossella Carello; Antonio Pizzuti; Marco G Paggi; Roberto Paganelli; Walter Malorni; Fernando Aiuti
Journal:  J Immunol       Date:  2007-03-15       Impact factor: 5.422

Review 2.  CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy.

Authors:  Ryuma Tokunaga; Wu Zhang; Madiha Naseem; Alberto Puccini; Martin D Berger; Shivani Soni; Michelle McSkane; Hideo Baba; Heinz-Josef Lenz
Journal:  Cancer Treat Rev       Date:  2017-11-26       Impact factor: 12.111

3.  Altered gut microbiota profile in common variable immunodeficiency associates with levels of lipopolysaccharide and markers of systemic immune activation.

Authors:  S F Jørgensen; M Trøseid; M Kummen; J A Anmarkrud; A E Michelsen; L T Osnes; K Holm; M L Høivik; A Rashidi; C P Dahl; M Vesterhus; B Halvorsen; T E Mollnes; R K Berge; B Moum; K E A Lundin; B Fevang; T Ueland; T H Karlsen; P Aukrust; J R Hov
Journal:  Mucosal Immunol       Date:  2016-03-16       Impact factor: 7.313

4.  Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay.

Authors:  Lea C Berkhout; Merel J l'Ami; Jill Ruwaard; Margreet H Hart; Pleuni Ooijevaar-de Heer; Karien Bloem; Michael T Nurmohamed; Ronald F van Vollenhoven; Maarten Boers; Daniel F Alvarez; Catherine H Smith; Gerrit J Wolbink; Theo Rispens
Journal:  Sci Transl Med       Date:  2019-01-30       Impact factor: 17.956

5.  Common variable immunodeficiency disorders: division into distinct clinical phenotypes.

Authors:  Helen Chapel; Mary Lucas; Martin Lee; Janne Bjorkander; David Webster; Bodo Grimbacher; Claire Fieschi; Vojtech Thon; Mohammad R Abedi; Lennart Hammarstrom
Journal:  Blood       Date:  2008-03-04       Impact factor: 22.113

Review 6.  CD83: Activation Marker for Antigen Presenting Cells and Its Therapeutic Potential.

Authors:  Ziduo Li; Xinsheng Ju; Pablo A Silveira; Edward Abadir; Wei-Hsun Hsu; Derek N J Hart; Georgina J Clark
Journal:  Front Immunol       Date:  2019-06-07       Impact factor: 7.561

7.  Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma.

Authors:  Anne Fröhlich; Sophia Loick; Emma Grace Bawden; Simon Fietz; Jörn Dietrich; Eric Diekmann; Gonzalo Saavedra; Holger Fröhlich; Dennis Niebel; Judith Sirokay; Romina Zarbl; Gerrit H Gielen; Glen Kristiansen; Friedrich Bootz; Jennifer Landsberg; Dimo Dietrich
Journal:  EBioMedicine       Date:  2020-02-03       Impact factor: 8.143

8.  Predominantly Antibody-Deficient Patients With Non-infectious Complications Have Reduced Naive B, Treg, Th17, and Tfh17 Cells.

Authors:  Emily S J Edwards; Julian J Bosco; Pei M Aui; Robert G Stirling; Paul U Cameron; Josh Chatelier; Fiona Hore-Lacy; Robyn E O'Hehir; Menno C van Zelm
Journal:  Front Immunol       Date:  2019-11-15       Impact factor: 7.561

9.  Galectin-9 and CXCL10 as Biomarkers for Disease Activity in Juvenile Dermatomyositis: A Longitudinal Cohort Study and Multicohort Validation.

Authors:  Judith Wienke; Felicitas Bellutti Enders; Johan Lim; Jorre S Mertens; Luuk L van den Hoogen; Camiel A Wijngaarde; Joo Guan Yeo; Alain Meyer; Henny G Otten; Ruth D E Fritsch-Stork; Sylvia S M Kamphuis; Esther P A H Hoppenreijs; Wineke Armbrust; J Merlijn van den Berg; Petra C E Hissink Muller; Janneke Tekstra; Jessica E Hoogendijk; Claire T Deakin; Wilco de Jager; Joël A G van Roon; W Ludo van der Pol; Kiran Nistala; Clarissa Pilkington; Marianne de Visser; Thaschawee Arkachaisri; Timothy R D J Radstake; Anneke J van der Kooi; Stefan Nierkens; Lucy R Wedderburn; Annet van Royen-Kerkhof; Femke van Wijk
Journal:  Arthritis Rheumatol       Date:  2019-03-12       Impact factor: 10.995

10.  Adiponectin Receptors and Pro-inflammatory Cytokines Are Modulated in Common Variable Immunodeficiency Patients: Correlation With Ig Replacement Therapy.

Authors:  Rita Polito; Ersilia Nigro; Antonio Pecoraro; Maria Ludovica Monaco; Franco Perna; Alessandro Sanduzzi; Arturo Genovese; Giuseppe Spadaro; Aurora Daniele
Journal:  Front Immunol       Date:  2019-11-27       Impact factor: 7.561

View more
  3 in total

1.  Raised Serum Markers of T Cell Activation and Exhaustion in Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency.

Authors:  Mai Sasaki Aanensen Fraz; Annika Elisabet Michelsen; Natasha Moe; Trond Mogens Aaløkken; Magnhild Eide Macpherson; Ingvild Nordøy; Pål Aukrust; Eli Taraldsrud; Are Martin Holm; Thor Ueland; Silje Fjellgård Jørgensen; Børre Fevang
Journal:  J Clin Immunol       Date:  2022-07-05       Impact factor: 8.542

2.  Contribution of Helicobacter pylori to the Inflammatory Complications of Common Variable Immunodeficiency.

Authors:  Adriana Motta-Raymundo; Pedro Rosmaninho; Diana F Santos; Ruben D Ferreira; Sara P Silva; Cristina Ferreira; Ana E Sousa; Susana L Silva
Journal:  Front Immunol       Date:  2022-05-31       Impact factor: 8.786

Review 3.  Seeking Relevant Biomarkers in Common Variable Immunodeficiency.

Authors:  Hsi-En Ho; Charlotte Cunningham-Rundles
Journal:  Front Immunol       Date:  2022-03-11       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.